Skip to Main Content

Paper Details

Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio: A Secondary Analysis of the RESCUE Clinical Trial.
JAMA Cardiology
7
2023
-, C-reactive, Chronic Renal Disease, IL-1, IL-6, IL-6 ligand, Interleukin (IL) 1, Interleukin 6, Lymphocyte, NLR, Neutrophil, Participants, Patients, Ziltivekimab, atherosclerosis, atherosclerotic, chronic kidney disease, diabetes, lymphocyte, men, myeloid cell compartment, neutrophil, participants, women, ziltivekimab
Author NameAffiliation
Peter LibbyBrigham and Women's Hospital, Harvard Medical School
Paul M RidkerCenter for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School
Paul M RidkerBrigham and Women's Hospital, Harvard Medical School
  • 1 - 3

Datasets

Release 1.2